Credit Suisse Downgrades Teladoc from Outperform to Neutral, Says Q1 Results in Line, But Full-Year Outlook Disappointing; Lowers price target to $35 from $114


Newswires MT 2022

All news about TELADOC HEALTH, INC.

Analyst Recommendations for TELADOC HEALTH, INC.

2022 sales 2,430M

2022 net income -6,939M

Net debt 2022 358M

PER 2022 ratio -1.30x
2022 return
Capitalization 9,022 million
9,022 million
EV / Sales 2022 3.86x
EV / Sales 2023 2.85x
# of employees 4,718
Floating 99.4%


Duration :

Period :

Teladoc Health, Inc. Technical Analysis Chart |  MarketScreener

Trends Technical Analysis TELADOC HEALTH, INC.

Short term Middle term Long term
Tendencies Bearish Bearish Bearish

Evolution of the income statement

To sell

To buy

Medium consensus SURPASS
Number of analysts 29
Last closing price $55.99
Average target price $99.26
Average Spread / Target 77.3%


Comments are closed.